INM Stock Whipsaws As InMed Refines Mentari Merger Terms

InMed Pharmaceuticals Inc. stocks have been trading up by 11.7 percent following positive coverage of its cannabinoid-based drug pipeline.

Live Update At 14:04:59 EDT: On Wednesday, July 22, 2026 InMed Pharmaceuticals Inc. stock [NASDAQ: INM] is trending up by 11.7%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

INM has been trading like a true small-cap biotech — thin, jumpy, and headline driven. Over the last few weeks, InMed Pharmaceuticals drifted in a tight band around $1.50–$1.60, then suddenly ripped to an intraday premarket high above $5 before fading to close near $1.73. That’s a huge range for one session and tells traders this tape can move fast when volume shows up.

From a fundamentals angle, INM is classic development-stage biotech. Revenue is tiny at roughly $4.9M, yet growing sharply over three years, but profitability is deep in the red. Profit margins and return ratios are heavily negative, which is normal for a company funding R&D rather than pumping out steady profits.

More Breaking News

• Western Digital Stock Rallies As Street Hikes Targets And Merger Talk Returns
• CPHI Stock Whipsaws As Company Denies Hidden News
• SHAZ Stock Pulls Back As Traders Watch Key Support
• UTZ Brands Rallies Behind Boulder Canyon Awards And Campaign

On the positive side, InMed Pharmaceuticals’ balance sheet shows around $5.2M in cash and a current ratio above 3, with very low debt. That gives INM some breathing room, but the negative free cash flow near -$1.7M in the latest quarter signals more capital raises are likely over time. For traders, that mix — small float, ongoing cash burn, and active deal news — creates a setup where catalysts matter more than traditional value metrics.

Why Traders Are Watching The Mentari Deal

INM is squarely on radar because corporate action often drives the biggest moves in tiny biotechs. InMed Pharmaceuticals amended its definitive all-stock merger agreement with Mentari Therapeutics and, at the same time, filed a Form S-4 and preliminary proxy/prospectus with the SEC. That combo signals the company is serious about getting this transaction across the finish line.

The amendment itself is not flashy. It cleans up the order in which steps of the deal will happen, clarifies how any pre-closing financing will change the share-exchange ratio, and spells out intended tax treatment. But for traders in INM, those “boring” details are exactly where dilution risk and deal value hide.

If InMed Pharmaceuticals raises capital before closing, the exchange ratio will shift. That changes how much of the combined company current INM holders end up owning. The boards of both InMed and Mentari have already signed off on the merger, and the target closing window is Q4 2026, subject to shareholder approval and S-4 effectiveness. So structurally, the path is laid out.

In the meantime, the chart is telling its own story. INM spiked hard off the open, tagged extreme premarket highs, then bled lower through the day with wide 5-minute candles. That’s textbook “news pop then profit-taking.” Short-term traders are scalping volatility while longer-term players are trying to handicap what the final Mentari terms mean for their slice of the pie.

Conclusion

For active traders, INM is now a merger-and-financing story layered on top of a volatile small-cap biotech chart. InMed Pharmaceuticals has modest revenue, heavy operating losses, and strong but finite cash levels. The amended Mentari Therapeutics deal and the new S-4 filing move the process forward but don’t remove the big overhang — how much new stock INM might issue before closing and at what terms.

That’s where disciplined chart work matters. The recent intraday range from the $5 area down toward the mid-$1s shows how quickly sentiment in InMed Pharmaceuticals can flip. Any fresh update on SEC review, shareholder votes, or pre-closing capital raises could spark another round of sharp trading both ways.

Traders who track INM need to study the S-4, watch volume, and respect risk. You are not dealing with a steady blue chip here; you are trading a story stock tied to execution on a complex, all-stock merger. As Tim Sykes loves to remind traders, “patterns repeat, but you still have to cut losses quickly when they fail.” As Tim Bohen, lead trainer with StocksToTrade says, “There’s a pattern in everything; you just have to stick around long enough to see it.” That mindset fits INM perfectly — use the volatility around the Mentari deal as an educational lab, not a lottery ticket.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

• How to Read Stock Charts: A Guide for Beginners
• Trading Plan: 6 Steps to Create One
• How To Create a Stock Watchlist

Ready to build your watchlists? Check out these curated lists:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.